We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout
Read MoreHide Full Article
Catalent, Inc. (CTLT - Free Report) recently reached an agreement to acquire RheinCell Therapeutics GmbH, which is expected to close before the end of 2021, subject to customary conditions. Financial details of the transaction have been kept under wraps.
For investors’ note, RheinCell is a developer and manufacturer of GMP-grade human-induced pluripotent stem cells (iPSCs). The buyout will enable Catalent to offer the building blocks to scale iPSC-based cell therapies as well as reduce entry barriers to the clinic for therapeutic companies.
The completion of the buyout is expected to help Catalent significantly strengthen its foothold in the global Cell and Gene Therapy business. Notably, the business is a component of the company’s broader Biologics segment.
Rationale Behind the Deal
Catalent’s existing custom cell therapy process development and manufacturing capabilities are expected to get a significant boost via the buyout with proprietary GMP cell lines for iPSC-based therapies. iPSCs, which are cells that can be differentiated into various cell types, can be utilized to address a variety of therapeutic indications.
Per Catalent’s management, the provision of a renewable and standardized source of cells for further product development in the form of iPSCs can potentially turn out to be a disruptive technology. This technology could further propel the development of the next generation of cell therapies, thereby substantially enhancing the manufacturing ability at scale.
Industry Prospects
Per a report by The Business Research Company, the global cell and gene therapy market is expected to grow from $6.69 billion in 2020 to $17.32 billion in 2025 at a CAGR of 21%. Factors like increasing incidences of cancer and other chronic diseases, and rising number of clinical trials are likely to drive the market.
Given the market potential, the latest buyout is expected to significantly strengthen Catalent’s global business.
Of late, its enormous market prospect is making the cell and gene therapy market a happy hunting ground for its industry bigwigs. Recently, another renowned player in this space, PerkinElmer, Inc. , inked a deal to acquire SIRION Biotech GmbH. The latest buyout is likely to be an important addition to PerkinElmer’s growing cell and gene therapy research and development activities.
Other Notable Deals of Catalent
Of late, Catalent has entered into a few strategic deals across its businesses.
The company, in May, announced that it has begun a global innovation partnership with Norwegian biotech company Hofseth BioCare ASA to develop a delayed-release formulation of HBC’s OmeGo fish oil.
The same month, Catalent acquired Promethera Biosciences’ cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA, including its 32,400 square-foot (3,010 square-meter) facility in Gosselies, Belgium.
In April, the company partnered with gene therapy company AavantiBio to support the development and manufacturing of the latter’s gene therapies, including its lead program in Friedreich’s Ataxia.
Price Performance
Shares of the company have gained 51.7% in the past year compared with the S&P 500's 42.4% rise. The industry lost 7.4% in the said time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Catalent carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout
Catalent, Inc. (CTLT - Free Report) recently reached an agreement to acquire RheinCell Therapeutics GmbH, which is expected to close before the end of 2021, subject to customary conditions. Financial details of the transaction have been kept under wraps.
For investors’ note, RheinCell is a developer and manufacturer of GMP-grade human-induced pluripotent stem cells (iPSCs). The buyout will enable Catalent to offer the building blocks to scale iPSC-based cell therapies as well as reduce entry barriers to the clinic for therapeutic companies.
The completion of the buyout is expected to help Catalent significantly strengthen its foothold in the global Cell and Gene Therapy business. Notably, the business is a component of the company’s broader Biologics segment.
Rationale Behind the Deal
Catalent’s existing custom cell therapy process development and manufacturing capabilities are expected to get a significant boost via the buyout with proprietary GMP cell lines for iPSC-based therapies. iPSCs, which are cells that can be differentiated into various cell types, can be utilized to address a variety of therapeutic indications.
Per Catalent’s management, the provision of a renewable and standardized source of cells for further product development in the form of iPSCs can potentially turn out to be a disruptive technology. This technology could further propel the development of the next generation of cell therapies, thereby substantially enhancing the manufacturing ability at scale.
Industry Prospects
Per a report by The Business Research Company, the global cell and gene therapy market is expected to grow from $6.69 billion in 2020 to $17.32 billion in 2025 at a CAGR of 21%. Factors like increasing incidences of cancer and other chronic diseases, and rising number of clinical trials are likely to drive the market.
Given the market potential, the latest buyout is expected to significantly strengthen Catalent’s global business.
Of late, its enormous market prospect is making the cell and gene therapy market a happy hunting ground for its industry bigwigs. Recently, another renowned player in this space, PerkinElmer, Inc. , inked a deal to acquire SIRION Biotech GmbH. The latest buyout is likely to be an important addition to PerkinElmer’s growing cell and gene therapy research and development activities.
Other Notable Deals of Catalent
Of late, Catalent has entered into a few strategic deals across its businesses.
The company, in May, announced that it has begun a global innovation partnership with Norwegian biotech company Hofseth BioCare ASA to develop a delayed-release formulation of HBC’s OmeGo fish oil.
The same month, Catalent acquired Promethera Biosciences’ cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA, including its 32,400 square-foot (3,010 square-meter) facility in Gosselies, Belgium.
In April, the company partnered with gene therapy company AavantiBio to support the development and manufacturing of the latter’s gene therapies, including its lead program in Friedreich’s Ataxia.
Price Performance
Shares of the company have gained 51.7% in the past year compared with the S&P 500's 42.4% rise. The industry lost 7.4% in the said time frame.
Zacks Rank & Key Picks
Currently, Catalent carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
Veeva Systems’ long-term earnings growth rate is estimated at 15.8%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>